Skip to main content
Clinical Trials/NCT06319859
NCT06319859
Completed
Phase 3

Intrathecal Non-preservative-free Morphine With Bupivacaine Versus Intrathecal Bupivacaine Alone for Analgesia in Unilateral Inguinal Hernia Repair Surgeries: A Randomized Controlled Clinical Trial.

Cairo University1 site in 1 country50 target enrollmentAugust 3, 2024

Overview

Phase
Phase 3
Intervention
Morphine
Conditions
Pain, Postoperative
Sponsor
Cairo University
Enrollment
50
Locations
1
Primary Endpoint
Time to first analgesic requirement
Status
Completed
Last Updated
4 months ago

Overview

Brief Summary

This study will evaluate the efficacy and safety of intrathecal non-preservative-free morphine and its effect on pain in patients undergoing unilateral inguinal hernia surgeries.

Registry
clinicaltrials.gov
Start Date
August 3, 2024
End Date
November 25, 2025
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

AbdElKhalik Mahmoud Shaban

Lecturer of anaesthesia

Cairo University

Eligibility Criteria

Inclusion Criteria

  • Patients aged 18-65 years old.
  • Both genders.
  • ASA I and II class.

Exclusion Criteria

  • Patient refusal.
  • Known local anesthetic (LA) allergy.
  • Skin lesions or infections at the site of needle insertion.
  • Contraindications to spinal anesthesia.
  • Failure of spinal anesthesia.
  • ASA III and VI class.
  • Central or peripheral neuropathies.
  • Severe respiratory or cardiac diseases.

Arms & Interventions

Group A

patients will receive 0.1 mg morphine with 15 mg heavy bupivacaine intrathecally

Intervention: Morphine

Group B

patients will receive 15 mg heavy bupivacaine with 0.1 ml saline intrathecally

Intervention: Placebo

Outcomes

Primary Outcomes

Time to first analgesic requirement

Time Frame: 48 hours post-operatively

The time to first analgesic required by the patient will be recorded

Secondary Outcomes

  • The incidence of other adverse effects(14 days post-operatively)
  • Nalbuphine consumption(48 hours post-operatively)
  • Postoperative pain(at 2, 4,8,12,18,24,30,36,42, and 48 hours post-operatively)

Study Sites (1)

Loading locations...

Similar Trials